Epirubicin hydrochloride injection 50 mg/25 mL (11)

Land: Australia

Språk: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv ingrediens:

epirubicin hydrochloride, Quantity: 2 mg/mL

Tilgjengelig fra:

Pfizer (Perth) Pty Ltd

Legemiddelform:

Injection, solution

Sammensetning:

Excipient Ingredients: sodium chloride; hydrochloric acid; water for injections

Administreringsrute:

Intravenous Infusion, Intravesical

Enheter i pakken:

1 x 25 mL

Resept typen:

(S1) This Schedule is intentionally blank

Indikasjoner:

Intravenous Farmorubicine as monotherapy has shown an antitumour activity in breast carcinoma, gastric carcinoma and also in soft tissue sarcoma. In addition, objective responses have been observed in a smaller number of patients treated for a certain number of other tumours (pancreatic, ovarian, non-Hodgkin's lymphoma). Farmorubicine can be included in polychemotherapy regimens because it is less cardiotoxic than doxorubicin. Intravesical administration of epirubicin has produced positive results in superficial bladder tumours, both in therapeutic use and prophylactic use after transurethral resection. However, intravesical instillation is contra-indicated in the treatment of an invasive tumour that has penetrated the bladder wall.

Produkt oppsummering:

Visual Identification: Clear and clean red solution; Container Type: Vial; Container Material: PP; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Autorisasjon status:

Listed (Export Only)

Autorisasjon dato:

2018-11-09